Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, ...

Vertex Pharmaceuticals (VRTX ... At the same time, the Dow lost 0.07%, and the tech-heavy Nasdaq lost 0.9%. Shares of the drugmaker witnessed a loss of 14.25% over the previous month, trailing ...

DA Davidson analyst William Jellison initiated coverage of Vertex (VERX) with a Buy rating and $62 price target Vertex “exhibits several characteristics exemplifying sustained value-capture and ...

Vertex Pharmaceuticals (VRTX ... Elsewhere, the Dow gained 0.91%, while the tech-heavy Nasdaq added 1.35%. The the stock of drugmaker has fallen by 12.22% in the past month, lagging the Medical ...

In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

Investment analysts at DA Davidson started coverage on shares of Vertex (NASDAQ:VERX – Get Free Report) in a note issued to investors on Tuesday,Briefing.com Automated Import reports.

Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) shareholders might be concerned after seeing the share price ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...